• CSL's Gene Therapy Approval Marks First for Hemophilia B and New High in Pricing

    6 days ago - By MedCity News

    CSL Behring's hemophilia B gene therapy, Hemgenix, carries a $3.5 million list price. But the company contends that by reducing economic burdens associated with bleeding and prophylactic infusions, the one-time treatment will save money over time.
    Read more ...